10 citations
,
July 2023 in “Pharmaceutics” In this study using mice and human keratinocyte cells, researchers found that activating PKM2-mediated glycolysis and Wnt/β-catenin signaling, particularly via combined treatments, significantly accelerated wound healing and induced angiogenesis in wound beds.
7 citations
,
March 2017 in “Actas Dermo-Sifiliográficas” This review summarizes recent therapeutic advancements in treating various forms of alopecia, including new applications of oral minoxidil, dutasteride, finasteride, Janus kinase inhibitors, and novel hair transplant techniques, without presenting original research results.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.
4 citations
,
January 2025 in “JAAD reviews.” This review discusses how JAK inhibitors, like tofacitinib and baricitinib, show promise in improving conditions like lichen planopilaris and frontal fibrosing alopecia by reducing severity scores and enhancing hair regrowth, though further research on safety and personalized approaches is needed.
4 citations
,
September 2020 in “Cell division” In this study, XMU-MP-1 unexpectedly reduced cell proliferation and altered cell cycle progression in a model human hair follicle, possibly due to off-target kinase inhibition.
3 citations
,
July 2021 in “Life science alliance” This study observed that disrupting the Pnkp gene in adult mice resulted in a premature aging-like phenotype, suggesting PNKP's vital role in maintaining normal growth and survival of certain progenitor cell populations.
2 citations
,
October 2025 in “Cells” This review discusses the multifunctional role of PKM2 in promoting cardiac repair and regeneration, highlighting its potential as a therapeutic target in cardiovascular medicine, but reports no new experimental results.
2 citations
,
December 2022 in “Pharmaceutics” This study found that activating both PKM2 and Wnt/β-catenin signaling pathways significantly enhanced hair regrowth and hair follicle neogenesis in mice, suggesting a potential strategy for treating alopecia.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.
March 2026 in “JMIR Dermatology” This article highlights the rising interest in Janus kinase inhibitors for alopecia areata, especially following the FDA approval of baricitinib, underscoring the need for better patient education and physician guidance in selecting appropriate treatments for hair loss.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy. Discontinuation of rituximab and initiation of oral baricitinib led to improvement in skin conditions, underscoring potential immune-related skin effects from rituximab.
January 2026 in “Journal of Clinical Medicine” The study found that systemic inflammatory markers were elevated in patients with severe alopecia areata compared to those with mild disease and healthy controls, and these markers decreased in patients who improved after JAK inhibitor therapy.
January 2026 in “International Journal of All Research Education & Scientific Methods” This review highlights recent advancements in understanding and treating alopecia, emphasizing genetic and immune factors involved in different forms, and discusses emerging therapies such as gene-editing and exosome-based treatments, though achieving complete hair regrowth remains a challenge.
December 2025 in “Biomedicines” This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.
October 2025 in “Dermatology and Therapy” This study reviewed the literature on atopic dermatitis and found a strong connection with several other skin conditions, such as psoriasis and alopecia areata, while highlighting potential treatments like JAK inhibitors and dupilumab that show promise for these comorbidities.
September 2025 in “International Journal of Science and Research (IJSR)” This theoretical review analyzes how stress affects hair loss through hormonal and neural pathways, indicating that knowledgeable hairdressers could help in early detection and guide clients toward medical interventions, highlighting a potential collaboration between aesthetic care and medical treatment for stress-induced alopecia.
April 2025 in “Turkish Journal of Hematology” Nilotinib may cause gray hair to return to its original color.
August 2024 in “Journal of Animal Science and Technology” This study identified specific keratin-associated protein genes that are highly expressed in different varieties and sexes of Angora goats, providing insights for improving mohair development through targeted breeding strategies.
April 2024 in “Journal of pharmacy & pharmacognosy research” This study used in silico analysis to identify 4-[2-(4-nitrophenyl)ethylcarbamoyl]benzenesulfonyl as a potential inhibitor of the EGFR mutant associated with NSCLC, highlighting the need for further in vitro and in vivo validation.
March 2024 in “Clinical, cosmetic and investigational dermatology” This study reported that five patients with alopecia areata achieved satisfactory results using 15 mg of Upadacitinib daily after conventional treatments had failed, without experiencing adverse events.
December 2023 in “Journal of clinical medicine” This study reports the case of an elderly patient with a keratosis pilaris-like skin eruption after beginning treatment with imatinib for chronic myeloid leukemia, discussing similar skin reactions to BCR-ABL inhibitors and exploring potential mechanisms behind these adverse cutaneous reactions.
July 2023 in “Dermatology and therapy” In patients with alopecia areata, this study found elevated levels of venous thromboembolism markers SFMC and F1 + 2 compared to healthy controls, potentially indicating an increased risk for this condition.
June 2023 in “Dermatology and therapy” This study found that most dermatologists in the Middle East manage mild to severe alopecia areata primarily with potent topical corticosteroids and identified long-term disease control and improved efficacy as key unmet needs.
This study found that PRL-1-overexpressing PD-MSCs reduced adipogenesis in orbital fibroblasts from Graves' ophthalmopathy patients by secreting IGFBPs and modulating the FAK pathway.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.
81 citations
,
February 2019 in “Experimental & Molecular Medicine” This review examines PAK4 signaling pathways in prostate cancer, Parkinson's disease, and melanogenesis, focusing on the potential role of the PAK4-CREB axis, without reporting new clinical results.
14 citations
,
July 2021 in “Biomolecules” This study found that Centipeda minima extract promotes hair growth by activating Wnt/β-catenin, ERK, and JNK signaling pathways in human hair follicle dermal papilla cells.
8 citations
,
July 2024 in “Journal of Advanced Research” In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.
6 citations
,
May 2022 in “Frontiers in physiology” This study suggests that an in ovo injection of CHIR-99021 promoted feather growth and follicle development in goose embryos by activating the Wnt signaling pathway.
3 citations
,
October 2024 in “Frontiers in Medicine” This study investigated single-cell changes in photoaged skin, revealing distinct cell clusters and increased activity in PD-L1 and PD-1 pathways in sun-exposed areas, enhancing understanding of UVA-induced skin damage and potential prevention targets for photoaging and UV-induced skin cancers.